Anti-Venom Market by Type and Geography - Forecast and Analysis 2022-2026

“The Anti-Venom Market is poised to grow by $ 481.51 mn during 2022-2026, accelerating at a CAGR of 7.82% during the forecast period”

Anti-Venom is purified antibodies against venoms or venom components. Antivenoms are produced from antibodies made by animals to injected venoms. The primary use of anti-venom is for the treatment of snakebites has been the administration of antivenoms & also boosting our immune response after a snakebite. They are made by immunizing donor animals such as horses or sheep with snake venoms.

Technavio market report provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 15 vendors. Furthermore, this report extensively covers the Anti-Venom Market segmentation by type of polyvalent anti-venom and monovalent anti-venom and other anti-venom types and geography North America, Asia, Europe, and ROW. The Anti-Venom Market report also offers information on several market vendors, including Bharat Serums and Vaccines Ltd., Boehringer Ingelheim International GmbH, CSL Ltd., Haffkine bio pharmaceutical Corp. Ltd., Merck KGaA, Pfizer Inc., Rare Disease Therapeutics Inc., SERB Sarl, Serum Institute of India Pvt. Ltd., and VINS Bioproducts Ltd. among others.

What will the Anti-Venom Market Size be During the Forecast Period?

Download Report Sample to Unlock the Anti-Venom Market Size for the Forecast Period and Other Important Statistics

Parent Market Analysis

Our Technavio Research categorizes the global report belonging to Pharmaceuticals, Biotechnology & Life Sciences and with a segment of polyvalent anti-venom and two more segments for the market. Technavio is based on four simple principles: easy-to-access reports, robust industry coverage, a focus on new and emerging technologies, and competitive pricing. We believe in helping companies and executives become better equipped to make faster, sounder, and more effective decisions.

Anti-Venom Market: Key Drivers, Trends, and Challenges

The rising prevalence of venomous bites and stings is notably driving the market growth, although factors such as the high cost of available anti-venoms may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic's impact on the smart room heater industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Anti-Venom Market Driver

The healthcare and biotechnology industry is witnessing significant demand from developing economies globally. The key factor that drives the growth of the market is the demand for anti-venom treatment being the only authorized treatment for snakebites. Destroying forest lands for agricultural and housing purposes has increased the proximity of human beings to poisonous insects and animals such as snakes, spiders, bees, and scorpions, which, in turn, increases the prevalence of venomous bites. The high prevalence of snakebites, scorpion bites, and other animal or insect bites, such as fish stings, is driving the growth of the market.

Key Anti-Venom Market Challenge

The total cost of tendinitis treatment is considerably high, as the total cost includes clinical trials, legal costs, hospital fees, and US FDA fees. Furthermore, the process of making anti-venom is quite complicated. It involves injecting sheep with snake venom and harvesting and processing the resulting antibodies made by their immune systems. This makes it expensive. In addition, non-consistent reimbursement policies in different countries as well increase the total cost. Therefore, the high cost of anti-venoms is expected to negatively impact the growth of the market during the forecast period. 

This market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.

Market Overview

The parent pharmaceuticals market covers products and companies engaged in the R&D or production of generic drugs, non-generic drugs, and veterinary drugs. Technavio calculates the global healthcare market size based on the combined revenue generated by manufacturers/providers of equipment, supplies, pharmaceuticals, biotechnology, and life sciences tools and services. 

Technavio is a global technology research and advisory company. We use a proprietary Research Methodology tailored to each market we cover. Unlike most vendors that provide similar reports, our team of Industry Experts constantly validates our data, assumptions, and conclusions based on in-depth research and over 50 years of combined experience in the IT Industry. Our data is completely original: it has not been aggregated or replicated. This creates a unique opportunity for you to obtain a comprehensive view of the current state of the market as well as provide deep insights into future outlook areas.

 

Who are the Major Anti-Venom Market Vendors?

The vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading smart room heater market vendors such as

• Bharat Serums and Vaccines Ltd.
• Boehringer Ingelheim International GmbH
• CSL Ltd.
• Haffkine bio pharmaceutical Corp. Ltd.
• Merck KGaA
• Pfizer Inc.
• Rare Disease Therapeutics Inc.
• SERB Sarl
• Serum Institute of India Pvt. Ltd.
• VINS Bioproducts Ltd.

The market is fragmented and the vendors are deploying various organic and inorganic growth strategies to compete in the market.

The inclusive growth scenario of the market is a significant opportunity for vendors, who should explore strategic options to penetrate new segments and successfully take on rivals in the market. These strategies include investment in R&D, developing and licensing technology, increasing production capacity and capacity optimization.

This market study provides key insights on the market including a vendor analysis, competitive landscape and growth drivers. The profiles include information on the production, sustainability, and prospects of the leading companies. 

Anti-Venom Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the anti-venom market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

Which are the Key Regions for Anti-Venom Market?

40% of the market's growth will originate from North America during the forecast period. The US is a key market for anti-venom in North America. However, the market growth rate in this region will be slower than the growth of the market in Asia.

The increasing number of products in the pipeline and the increased focus on R&D activities from both public and private organizations will facilitate market growth in North America over the forecast period. The demand for anti-venom is growing due to the increasing rate of mortality which drives the growth of the market in North America. Furthermore, the existence of key vendors such as Pfizer Inc., Rare Disease Therapeutics, Merck KGaA, Boehringer Ingelheim, and CSL Limited is one of the major factors that drive the growth of the regional market.This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

 The outbreak of COVID-19 negatively impacted the market in North America, especially in the US, in 2020. The growing number of COVID-19 cases led to lockdowns in several countries, including Canada and Mexico, in 2020. As a result, manufacturing units of various industries, including anti-venoms, were closed. This might negatively impact the growth of the market in North America during the first half of the forecast period. 

 

What are the Revenue-generating Type Segments in the Anti-Venom Market?

To gain further insights on the market contribution of various segments Request a PDF Sample

 

The anti-venom market share growth by the polyvalent anti-venom segment will be significant during the forecast period. Polyvalent anti-venoms saves the life of the victim even when the culprit snake is unknown, about 80% of all the time, in the most usual cases, and when a monovalent anti-venom cannot be chosen. Due to such beneficial advantages, polyvalent anti-venoms are the most preferred anti-venom drug. Polyvalent anti-venoms are generally useful in regions where a large number of venomous species are present and when it is difficult to produce monovalent anti-venoms against all of them. With the number of advantages of anti-venoms, key vendors dealing in the anti-venom market are focusing on developing polyvalent anti-venoms. 

The COVID-19 situation, most of the vendors temporarily shifted their focus from the development of anti-venoms to the development of treatment/vaccines for COVID-19. This affected the growth of this segment of the market in focus in 2020. However, with COVID-19 vaccination and improvement in the COVID-19 situation, this market segment recovered soon.

The report provides a near-term to long-term perspective on the trends and forecasts horizon for the anti-venom market. It offers an overview of the key market drivers and restraints, enabling precise identification of key opportunities in each region over the coming years.

Anti-Venom Market Scope
Report Coverage	Details
Page number	120
Base year	2021
Forecast period	2022-2026
Growth momentum & CAGR	Accelerate at a CAGR of 7.82%
Market growth 2022-2026	$ 481.51 million
Market structure	Fragmented
YoY growth (%)	7.10
Regional analysis	North America, Asia, Europe, and ROW
Performing market contribution	North America at 40%
Key consumer countries	US, China, Japan, India, and Germany
Competitive landscape	Leading companies, Competitive Strategies, Consumer engagement scope
Key companies profiled	Bharat Serums and Vaccines Ltd., Boehringer Ingelheim International GmbH, CSL Ltd., Haffkine bio pharmaceutical Corp. Ltd., Merck KGaA, Pfizer Inc., Rare Disease Therapeutics Inc., SERB Sarl, Serum Institute of India Pvt. Ltd., and VINS Bioproducts Ltd.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request PDF sample

What are the Key Data Covered in this Anti-Venom Market Report?

• CAGR of the market during the forecast period 2022-2026
• Detailed information on factors that will drive anti-venom market growth during the next five years
• Precise estimation of the anti-venom market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• The growth of the anti-venom market industry across North America, Asia, Europe, and ROW
• A thorough analysis of the market’s competitive landscape and detailed information on vendors
• Comprehensive details of factors that will challenge the growth of anti-venom market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch